Anticoagulant-Related Nephropathy.
Sergey Brodsky1, John Eikelboom2, Lee A Hebert3
1Renal and Transplant Pathology Laboratory, Department of Pathology and.
Journal of the American Society of Nephrology : JASN
|November 14, 2018
Summary
Anticoagulant-related nephropathy (ARN) is a newly identified kidney injury. New analysis suggests ARN is not rare in patients taking oral anticoagulants for atrial fibrillation.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Anticoagulant-related nephropathy (ARN) is a recently recognized cause of acute kidney injury (AKI).
- It is characterized by glomerular hemorrhage due to overanticoagulation, with tubules filled with red cells and casts on biopsy.
- Despite widespread oral anticoagulant use since the 1950s, ARN was only recently discovered, implying rarity.
Purpose of the Study:
- To review the discovery and confirmation of ARN.
- To present an animal model of ARN.
- To analyze existing data and provide recommendations for diagnosis and management.
Main Methods:
- Review of the literature on ARN discovery and confirmation.
- Description of a developed animal model for ARN.
- Analysis of
- renal events
- from post hoc analyses of anticoagulation trials and retrospective database studies.
Main Results:
- The initial discovery of ARN has been validated by numerous independent researchers.
- Analysis of existing clinical data suggests ARN may not be a rare complication in anticoagulated patients with atrial fibrillation.
- Significant biases exist in post hoc and retrospective analyses, highlighting the need for prospective studies.
Conclusions:
- ARN is an important consideration in patients on oral anticoagulation.
- Further prospective research is crucial to accurately determine the incidence and risk factors for ARN.
- Recommendations for diagnosis and management are provided based on current evidence.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.9K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.9K


